Asterand and Allergan in potential $62 million preclinical eye disease deal
This article was originally published in Scrip
Executive Summary
Asterand could receive up to $62.3 million after signing an exclusive licence agreement with Allergan on the development of preclinical compounds for eye diseases. Allergan gains the right to develop and commercialise certain selective, small-molecule prostaglandin receptor agonists from Asterand's R99 development programme to treat conditions such as glaucoma. Allergan will give Asterand an upfront technology access fee of $6.3 million and up to a further $56 million on success-based development and sales milestone payments, plus royalties. Asterand, which provides human tissue and services for drug discovery research, has other drug discovery programmes such as further prostaglandin agonists for immuno-inflammatory diseases and pre-term labour, and compounds for treating bone disease, cancer and irritable bowel syndrome. Martyn Coombs, Asterand CEO, says the company will seek out-licensing opportunities with other pharma companies.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.